Score Overview
Explore the 2021 public Archive ranking →
Where TG Therapeutics Inc has ranked, year by year
Showing 5 years ranking history by Net Income Growth.
Has not reached the top 50 on Net Income Growth in any year we have ranked.
- TGTX
2002: 46.5% · 2021: 91.2% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-30 | $ 55.78 | — |
1 Year2025-09-30 | $ 36.13 | 54.41% |
5 Years2021-09-30 | $ 33.28 | 67.61% |
10 Years2016-09-30 | $ 7.74 | 7x |
| Period | Last Price2026-09-30 | 1 Year2025-09-30 | 5 Years2021-09-30 | 10 Years2016-09-30 |
|---|---|---|---|---|
| Price | $ 55.78 | $ 36.13 | $ 33.28 | $ 7.74 |
| Return | — | 54.41% | 67.61% | 7x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 799M | $ 441M | $ 552M |
| 2025 | $ 616M | $ 447M | $ 141M |
| 2024 | $ 329M | $ 23M | $ 311M |
| 2023 | $ 233M | $ 12M | $ 217M |
| 2022 | $ 2M | -$ 223M | $ 161M |
| 2021 | $ 6M | -$ 348M | $ 314M |
| 2020 | $ 152K | -$ 279M | $ 605M |
| 2019 | $ 152K | -$ 172M | $ 140M |
| 2018 | $ 152K | -$ 173M | $ 68M |
| 2017 | $ 152.38K | -$ 118M | $ 84M |
| 2016 | $ 152.38K | -$ 78M | $ 44M |
| 2015 | $ 152.38K | -$ 62M | $ 102M |
| 2014 | $ 152.38K | -$ 55M | $ 78M |
| 2013 | $ 152.38K | -$ 20M | $ 45M |
| 2012 | $ 19.05K | -$ 18M | $ 16M |
| 2011 | $ 0.00 | -$ 853.07K | $ 9M |
| 2010 | $ 623.64K | $ 478.67K | |
| 2009 | -$ 2M | $ 18K | |
| 2008 | -$ 4M | $ 106.02K | |
| 2007 | -$ 12M | $ 649.69K | |
| 2006 | -$ 9M | $ 3M | |
| 2005 | -$ 19M | $ 10M | |
| 2004 | -$ 5M | $ 5M | |
| 2003 | -$ 5M | $ 7M | |
| 2002 | $ 500K | -$ 1M | $ 116.29K |
| 2001 | $ 2M | -$ 1M | $ 1M |
| 2000 | $ 5M | -$ 5M | $ 2M |
| 1999 | $ 1M | -$ 2M | $ 3M |
| 1998 | $ 3M | -$ 2M | $ 5M |
| 1997 | $ 100K | -$ 5M | $ 8M |
| 1996 | $ 100K | -$ 3M | $ 2M |
TG Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 152K to $ 616M and net income went from -$ 279M to $ 447M. Revenue increased in 4 of those 5 years; net income in 4.
Across TG Therapeutics Inc's full reported history, from 1996 to 2025, revenue grew from $ 100K to $ 616M and net income went from -$ 3M to $ 447M. Revenue increased in 43% of the years measured; net income in 47%.
TG Therapeutics Inc currently holds a 5-year HDB Score of 8.1 out of 10. How the HDB Score is calculated.
Membership
Continue TGTX’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
